Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

David Francis McDermott, M.D.

Co-Author

This page shows the publications co-authored by David McDermott and Kathleen Mahoney.
Connection Strength

1.106
  1. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma. Clin Ther. 2015 Apr 01; 37(4):764-82.
    View in: PubMed
    Score: 0.630
  2. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. Clin Genitourin Cancer. 2016 08; 14(4):304-313.e6.
    View in: PubMed
    Score: 0.168
  3. Vemurafenib-induced cardiac tamponade: a rare but potentially life-threatening complication. J Clin Oncol. 2013 Jul 20; 31(21):e364-6.
    View in: PubMed
    Score: 0.139
  4. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. Cancer Cell. 2021 05 10; 39(5):632-648.e8.
    View in: PubMed
    Score: 0.060
  5. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. Cancer Immunol Res. 2021 02; 9(2):156-169.
    View in: PubMed
    Score: 0.058
  6. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial. Clin Cancer Res. 2019 04 01; 25(7):2174-2184.
    View in: PubMed
    Score: 0.051
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.